Company intelligence / Profile preview
Yantai Dongcheng Pharmaceutical
- Ownership
- Private
- Employees
- ~2469
- Development stage
- Phase 1
Overview
Yantai Dongcheng Pharmaceutical is a leading Chinese pharmaceutical group with a strong focus on biochemical APIs and radiopharmaceuticals. The company has multiple approved products in China and globally for both diagnostic and therapeutic use in oncology and other indications. It holds significant market share in PET tracers in China and maintains robust R&D capabilities with several late-stage clinical programs targeting solid tumors using innovative radionuclide therapies.
- Therapeutic areas
- Men's HealthOncologyImmunologyRheumatologyCardiovascular
- Modalities
- Small moleculePeptidesRadiopharmaceuticals (Therapeutic radiopharmaceuticals, Diagnostic radiopharmaceuticals)
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Yantai Dongcheng Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yantai Dongcheng Pharmaceutical.